SOUTH SAN FRANCISCO, Calif., Nov 10, 2011 (BUSINESS WIRE) --

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael Morrissey, Ph.D., the company's president and chief executive officer, will present at the Lazard Capital Markets 8^th Annual Healthcare Conference at 10:00 a.m. EST / 7:00 a.m. PST on Tuesday, November 15, 2011, in New York. Dr. Morrissey will provide a general business update, review the most recent publicly available data for cabozantinib, and discuss the pivotal trial plans and regulatory strategy for the compound.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,Investor Relations and Corporate Communications
cbutler@exelixis.com